Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 0.76 |
| ▸ | MEN1 | O00255 | 3/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.76 |
| ▸ | LMNA | P02545 | 2/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.76 |
| ▸ | HPGD | P15428 | 1/20 | 0.76 |
| ▸ | CRHBP | P24387 | 1/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.76 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.76 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.76 |
| ▸ | GPR27 | Q9NS67 | 7/20 | 0.59 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.59 |
| ▸ | SLC10A6 | Q3KNW5 | 2/20 | 0.58 |
| ▸ | SLC10A2 | Q12908 | 1/20 | 0.58 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1138705 | 0.89 | SLC10A6 (0.63) | HTTMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL7109904 | 0.85 | MEN1 (0.55) | HTTMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL5124913 | 0.84 | SLC10A6 (0.57) | HTTMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL1138698 | 0.84 | KDM4E (0.64) | HTTMEN1KMT2ALMNAKDM4E | |
| SCHEMBL10249599 | 0.84 | GPR27 (0.66) | GPR27AVPR2SLC10A6SLC10A2SLC10A1 | |
| SCHEMBL1139427 | 0.84 | KMT2A (0.57) | HTTMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL5120009 | 0.83 | SLC10A6 (0.62) | HTTMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL6860504 | 0.83 | SLC10A6 (0.59) | HTTMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL6862400 | 0.83 | SLC10A6 (0.71) | MEN1KMT2AKDM4EGPR27AVPR2 | |
| SCHEMBL6754585 | 0.83 | SLC10A6 (0.81) | MEN1KMT2ALMNAALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0947500-B1 | SULFONAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2011-02-23 | — | — | EP | disclosed |
| EP-0947500-B1 | SULFONAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2011-02-23 | — | — | EP | disclosed |
| CN-1213019-C | Sulfonamide and carboxamide derivatives and drugs containing same as active ingredient | ONO PHARMACEUTICAL CO (JP) | 2005-08-03 | — | — | CN | disclosed |
| US-6790866-B2 | SUCH AS 4-(2-PHENYLSULFONYLAMINO-5-CHLOROBENZOYLAMINO)BENZOIC ACID FOR USE AS PROSTAGLANDIN E2 ANTAGONIST OR AGONIST; FOR INHIBITION OF UTERINE CONTRACTION, ANALGESICS, ANTIDIARRHEALS, SLEEP INDUCERS, AND/OR FOR INCREASE OF VESICAL CAPACITY | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-09-14 | — | — | US | disclosed |
| US-20030060460-A1 | Such as 4-(2-phenylsulfonylamino-5-chlorobenzoylamino)benzoic acid for use as prostaglandin E2 antagonist or agonist; for inhibition of uterine contraction, analgesics, antidiarrheals, sleep inducers, and/or for increase of vesical capacity | OHUCHIDA SHUICHI (JP) | 2003-03-27 | — | — | US | disclosed |
| US-6448290-B1 | PROSTAGLANDIN E2 ANTAGONIST OR AGONIST; INHIBITION OF UTERINE CONTRACTION, ANALGESICS, ANTIDIARRHEALS, SLEEP INDUCERS, INCREASING VESICAL CAPACITY, CATHARTIC, SUPPRESSION OF GASTRIC ACID SECRETION, ANTIHYPERTENSIVE, DIURETIC AGENTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-09-10 | — | — | US | disclosed |
| EP-0947500-A1 | SULFONAMIDE AND CARBOXAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 1999-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060460-A1 | Such as 4-(2-phenylsulfonylamino-5-chlorobenzoylamino)benzoic acid for use as prostaglandin E2 antagonist or agonist; for inhibition of uterine contraction, analgesics, antidiarrheals, sleep inducers, and/or for increase of vesical capacity | CNR1, HCAR1, HCAR2 | HTT 3078/4885MEN1 4832/4885KMT2A 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.